study to assess the efficacy and safety of brolucizumab 6mg compared to aflibercept 2 mg in a treat-to-control regimen (talon)

Conditions: Age-related Macular Degeneration

Summary: this was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (namd) who have not previously received anti- vascular endothelial growth factor (vegf) treatment.

at the baseline visit, subjects who met the eligibility criteria were randomized in a 1:1 ratio to receive either: -brolucizumab 6 mg: 3 × 4-week injections and one 8-week injection, followed by treat-to- control treatment from week 16 up to week 60/62 -aflibercept 2 mg: 3 × 4-week injections and one 8-week injection, followed by treat-to-control treatment from week 16 up to week 60/62. for all subjects, the last potential study treatment was at the week 60 visit (or at the week 62 visit for subjects whose actual treatment interval would require a treatment at week 62). the initiation phase starts on day 1 and ends on week 16. treat to control regimen starts on week 16 until end of treatment (week 60/62). in both treatment arms, treatment intervals after the initiation phase were either 8 weeks, 12 weeks, or 16 weeks. per the original protocol, if it was determined that a patient required more frequent injections than q8w, he/she would be moved to a q4w treatment interval. however, this option was removed per protocol amendment 02, after which, dosing intervals shorter than q8w were not permitted.

Eligibility criteria:
inclusion criteria: * signed informed consent must be obtained prior to participation in the study * male or female patients ≥ 50 years of age at screening who are treatment naive * active choroidal neovascularization (cnv) secondary to amd that affects the central subfield, including retinal angiomatous proliferation (rap) with a cnv component, confirmed by presence of active leakage from cnv seen by fluorescein angiography and sequellae of cnv, e.g. pigment epithelial detachment (ped), subretinal or sub-retinal pigment epithelium (sub-rpe) hemorrhage, blocked fluorescence, macular edema (study eye) * presence of intraretinal fluid (irf) or subretinal fluid (srf) that affects the central subfield, as seen by spectral domain optical coherence tomography (sd-oct) (study eye) * best-corrected visual acuity (bcva) score between 83 and 38 letters, inclusive, using early treatment diabetic retinopathy study (etdrs) visual acuity testing charts at both screening and baseline visit (study eye) exclusion criteria: * ocular conditions/disorders at screening or baseline which could, in the opinion of the investigator, prevent response to study treatment or may confound interpretation of study results, compromise visual acuity or require planned medical or surgical intervention during the first 12-month study period, structural damage of the fovea, atrophy or fibrosis at the center of the fovea (study eye) * any active intraocular or periocular infection or active intraocular inflammation, at screening or baseline (study eye) * uncontrolled glaucoma defined as intraocular pressure (iop) \> 25 mmhg on medication, or according to investigator's judgment, at screening or baseline (study eye) * ocular treatments: previous treatment with any anti-vascular endothelial growth factor (vegf) drugs or investigational drugs, intraocular or periocular steroids, macular laser photocoagulation, photodynamic therapy, vitreoretinal surgery, intraocular surgery (study eye) * stroke or myocardial infarction during the 6-month period prior to baseline * systemic anti-vegf therapy at any time.

Keywords: age-related macular degeneration macular degeneration wet macular degeneration retinal degeneration retinal diseases eye diseases amd namd wet amd rth258 brolucizumab double blind age-related macular degeneration (armd) vision loss macula damage retina damage dry macular degeneration subfoveal choroidal neovascularization (cnv) secondary to age-related macular degeneration